78% of 97 of patients positive for EGFR variant in primary had these mutations in ctDNA; EGFR:p.L858R in either tumor tissue or cfDNA predicts shorter OS and progression-free survival (PFS). ctDNA level correlate with total tumor volume. Here, EGFR is linked to neoplasm.